CAR-T Cell Therapy Clinical Trials in the UK 2026 — Find Active Studies
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) represents one of the most exciting advances in modern medicine. By genetically engineering your own immune cells to recognise and destroy cancer, CAR-T has achieved remarkable results in blood cancers that were previously untreatable. The UK is a major hub for CAR-T research, with trials now expanding from blood cancers into solid tumours and autoimmune diseases.
How CAR-T Cell Therapy Works
Your white blood cells are collected via an IV line. This takes 2-4 hours and is similar to donating blood. The T-cells are separated out and the rest of your blood is returned to you.
Your T-cells are sent to a specialised lab where a viral vector (usually a lentivirus or retrovirus) inserts the chimeric antigen receptor (CAR) gene. This reprogrammes them to target a specific protein on cancer cells. This takes 2-4 weeks.
The engineered CAR-T cells are multiplied in the lab to reach the therapeutic dose — typically millions to billions of cells. Quality control checks ensure the cells are safe and effective.
Before receiving your CAR-T cells, you'll typically have a short course of lymphodepleting chemotherapy to make space for the new cells. The CAR-T infusion itself takes just minutes, but you'll be monitored in hospital for 2-4 weeks.
CAR-T Trials by Condition
- Acute Lymphoblastic Leukaemia (ALL) — CD19-targeted CAR-T (tisagenlecleucel, brexucabtagene) is approved; trials focus on earlier lines and new constructs
- Diffuse Large B-Cell Lymphoma (DLBCL) — Multiple approved CAR-T products; trials testing in 2nd line and combinations
- Multiple Myeloma — BCMA-targeted CAR-T (ide-cel, cilta-cel) showing dramatic responses; next-gen dual-target CAR-T in trials
- Acute Myeloid Leukaemia (AML) — Early-phase trials targeting CD33, CD123, and other AML antigens
- Follicular Lymphoma & Mantle Cell — Expanding CAR-T into indolent lymphomas with promising results
- Solid Tumours — Early trials targeting GD2 (neuroblastoma), HER2, mesothelin, and other solid tumour antigens
Eligibility and Assessment
CAR-T trial eligibility is more complex than standard drug trials:
- Performance status — You need to be well enough to withstand the treatment process (typically ECOG 0-2)
- Organ function — Adequate heart, lung, liver, and kidney function required
- Disease-specific criteria — Specific markers like CD19 expression, BCMA expression, or disease refractory status
- Prior treatments — Most trials require failure of at least 2 prior lines of therapy
- No active infections — Including HIV, hepatitis B/C (some trials allow controlled HIV)
- T-cell fitness — Your collected T-cells must be healthy enough to be engineered
Important: CAR-T therapy requires specialised centres with expertise in cell therapy. UK CAR-T centres include The Christie (Manchester), UCLH (London), Birmingham, Glasgow, and others. Your referral pathway may depend on your nearest centre.
Side Effects and Monitoring
- Cytokine Release Syndrome (CRS) — The most significant side effect. Fever, low blood pressure, and difficulty breathing occur as CAR-T cells multiply and release inflammatory cytokones. Occurs in 30-90% of patients (most are mild). Treated with tocilizumab.
- Immune Effector Cell-Associated Neurotoxicity (ICANS) — Confusion, tremor, or difficulty speaking. Usually resolves within days. Close neurological monitoring is standard.
- Long-term B-cell aplasia — CD19-targeted CAR-T destroys normal B-cells too, requiring immunoglobulin replacement therapy.
- Infection risk — You'll be immunosuppressed for months. Prophylactic antibiotics and antivirals are standard.
Find Your Matching Trials
Answer a few questions about your condition and we'll show you the most relevant actively recruiting trials near you.
Find My Matching Trials →Browse CAR-T Cell Therapy Trials Search All Trials